Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 10:24AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.46 Insider Own5.98% Shs Outstand148.26M Perf Week4.23%
Market Cap292.07M Forward P/E- EPS next Y-0.17 Insider Trans0.55% Shs Float138.50M Perf Month13.22%
Income-64.40M PEG- EPS next Q-0.10 Inst Own38.76% Short Float6.96% Perf Quarter-37.66%
Sales171.36M P/S1.70 EPS this Y16.67% Inst Trans-3.02% Short Ratio5.44 Perf Half Y25.48%
Book/sh-0.06 P/B- EPS next Y53.78% ROA-19.58% Short Interest9.64M Perf Year-29.89%
Cash/sh0.59 P/C3.34 EPS next 5Y- ROE-617.16% 52W Range1.46 - 3.26 Perf YTD-16.17%
Dividend Est.- P/FCF- EPS past 5Y38.13% ROI-25.27% 52W High-39.57% Beta1.78
Dividend TTM- Quick Ratio1.81 Sales past 5Y195.35% Gross Margin76.58% 52W Low34.93% ATR (14)0.12
Dividend Ex-Date- Current Ratio2.37 EPS Y/Y TTM18.68% Oper. Margin-26.25% RSI (14)54.36 Volatility7.82% 6.28%
Employees377 Debt/Eq- Sales Y/Y TTM41.18% Profit Margin-37.58% Recom1.00 Target Price4.58
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-10.02% Payout- Rel Volume0.47 Prev Close1.98
Sales Surprise-3.71% EPS Surprise-32.08% Sales Q/Q22.42% EarningsMay 09 BMO Avg Volume1.77M Price1.97
SMA207.05% SMA50-0.06% SMA200-8.19% Trades Volume151,113 Change-0.51%
Date Action Analyst Rating Change Price Target Change
Mar-28-24Initiated Oppenheimer Outperform $5
Aug-28-23Initiated Craig Hallum Buy $4.50
Oct-21-22Initiated Jefferies Buy $4
Apr-28-22Initiated Craig Hallum Buy $6.50
Nov-17-21Initiated SVB Leerink Outperform $6
Oct-29-21Initiated H.C. Wainwright Buy $4
Apr-07-21Resumed RBC Capital Mkts Outperform $11
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
May-10-24 03:21PM
May-09-24 11:55AM
07:11AM Loading…
May-06-24 07:42AM
May-02-24 07:00AM
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
Mar-06-24 11:16PM
12:52PM Loading…
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
02:00PM Loading…
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
Nov-09-23 11:30AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-29-23 04:19PM
Jun-22-23 01:50PM
Jun-21-23 07:00AM
Jun-19-23 12:58PM
Jun-01-23 07:00AM
May-09-23 11:33PM
May-08-23 06:37AM
May-02-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 06:25AM
Apr-06-23 08:21AM
Apr-05-23 01:18PM
Mar-30-23 07:00AM
Mar-29-23 04:05PM
Mar-08-23 11:52PM
Feb-23-23 07:00AM
Feb-02-23 07:00AM
Jan-30-23 07:00AM
Jan-05-23 04:03PM
Dec-31-22 09:33AM
Dec-15-22 07:00AM
Nov-24-22 10:56AM
Nov-23-22 06:00AM
Nov-16-22 09:53AM
Nov-09-22 07:00AM
Nov-02-22 10:01AM
Nov-01-22 07:00AM
Oct-20-22 10:28AM
Oct-06-22 06:07AM
Sep-05-22 12:00PM
Aug-10-22 07:00AM
Aug-03-22 07:30AM
Aug-01-22 07:30AM
Jul-24-22 10:03AM
Jun-09-22 07:09AM
May-27-22 09:38AM
May-12-22 04:02PM
May-11-22 07:00AM
May-04-22 08:00AM
Mar-23-22 10:34AM
Mar-16-22 07:00AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schmid John P.DirectorMay 10 '24Buy1.915,40010,31416,400May 10 04:04 PM
JOHNSON JOHNDirectorMar 18 '24Option Exercise1.99215,600429,044751,412Mar 18 05:32 PM
Schmid John P.DirectorMar 14 '24Buy2.164,5009,72011,000Mar 14 09:03 PM
SHERMAN JEFFREY WDirectorNov 27 '23Buy1.875,40010,0985,400Nov 29 04:09 PM
Pieper StevenSee RemarksNov 20 '23Buy1.9528,00054,6001,176,912Nov 21 04:16 PM
HALKUFF DAWNDirectorNov 20 '23Buy1.845,4109,9545,410Nov 21 04:20 PM
Shannon John Patrick JrSee RemarksNov 17 '23Buy1.6430,76950,4001,408,575Nov 17 05:58 PM
Schmid John P.DirectorNov 16 '23Buy1.516,5009,8156,500Nov 17 06:35 PM
PERSKY MARLADirectorNov 14 '23Buy1.586,37010,0586,370Nov 15 04:13 PM
Edick Paul RSee RemarksAug 09 '23Buy2.3810,00023,7942,288,064Aug 09 06:57 PM